Anders Lönnberg has been a board member and chairman of Gabather since 2021. He has a master's degree in economics and is a healthcare politician. In 2015, Lönnberg was appointed by the government as national coordinator for Life Science issues. Lönnberg was a political expert in the Ministry of Social Affairs 1983-1987, State Secretary 1987-1990, chief negotiator at the airline SAS 1990-1994, federal director of SACO 1994-2001. After that he was a PR consultant at JKL and in his own company. He was Deputy CEO of the pharmaceutical company Novartis Sverige AB 2006-2011. Lönnberg has been a member of the council in Stockholm County Council since 1994. In the years 2002-2006, he was also a member of the County Council Board and chairman of its owner committee. Lönnberg has for several periods since 2015 served as a deputy in the Swedish Parliament: November 2015 to April 2016, April to August 2017 and September 2018 to January 2019. Lönnberg currently runs his own company in the consulting industry.
Shares: -
Warrants 22/25: 50 000
Independent in relation to the company, company management and to major shareholders.
Bert Junno has been a board member of Gabather since 2021. Bert has extensive experience of corporate management and board work for several companies active in electronics, biotechnology and IT in both Europe and the USA. Together with others, he has founded Gabather and several other biotechnology companies such as WntResearch AB, Galecto Biotech AB, Aptahem AB and Cyxone AB. Bert Junno holds a Ph.D. in Physics and Technology for Semiconductors and M.Sc. in physics from Lund University. Junno has previously been a board member of Taurus Energy AB (publ), Cardiovax llc., Galecto Biotech AB, Aptahem AB (publ), CEO and board member WntResearch AB (publ). He has also been the CEO and board member of Gabather. He resigned as CEO in 2018. Member of PRV's insight council 2010-2019.
Shares: -
Warrants: -
Not independent in relation to the company and company management.
Independent in relation to major shareholders.
Olov Sterner has been a board member of Gabather since 2014. Olov is an organic chemist specializing in the science of biologically active secondary metabolites. He was awarded the PhD degree in 1985, and after two years as a postoctoral fellow at the University of Bonn in Germany he got a position as researcher at Lund University. 1990 he became lecturer in organic chemistry, and since 1999 he is professor. His research efforts have until now resulted in more than 350 scientific publications in international journals, 23 patent applications and patents, and many conference contributions. He has, alone or with colleagues, written several textbooks in organic chemistry and chemical toxicology, and he is currently the head of the Department of Chemistry.
Shares: 106 532
Warrants: -
Independent in relation to the company, company management and to major shareholders.